Tag: AWAKN - Psychedelic Alpha

Access exclusive insights, data and interviews with Pα+: learn more and subscribe today.

Read more about the article Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway

Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway

Post published:April 13, 2022
Post category:Press Release

Read more about the article Awakn Life Sciences Announces Closing of Private Placement

Awakn Life Sciences Announces Closing of Private Placement

Post published:March 22, 2022
Post category:Press Release

Read more about the article Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments

Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments

Post published:March 17, 2022
Post category:Press Release

Read more about the article Awakn Files Patent For A New Class Of Entactogen-Like Molecules

Awakn Files Patent For A New Class Of Entactogen-Like Molecules

Post published:February 17, 2022
Post category:Press Release

Read more about the article Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions

Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions

Post published:January 26, 2022
Post category:Press Release

Read more about the article Awakn Life Sciences Signs MOU with Maps

Awakn Life Sciences Signs MOU with Maps

Post published:January 19, 2022
Post category:Press Release

Read more about the article Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial

Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial

Post published:January 11, 2022
Post category:Press Release

Read more about the article Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders

Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders

Post published:January 4, 2022
Post category:Press Release

Read more about the article Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights

Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights

Post published:December 15, 2021
Post category:Press Release

Read more about the article Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent Member of its Board of Directors

Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent Member of its Board of Directors

Post published:December 14, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.